Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses an evaluation of measurable residual disease (MRD) negativity in relapsed/refractory multiple myeloma (MM) patients in the Phase III Candor Study (NCT03158688). The results of the study from over 400 patients found that carfilzomib, dexamethasone (dex) and daratumumab (dara) (KdD) was superior to Kd in terms of progression-free survival. MRD was measured by next-generation sequencing of bone marrow samples. At the 12-month analysis, MRD-negativity was higher in patients in complete remission receiving KdD than Kd (12.5% vs 1.3%). Additionally, MRD responses were deeper in the KdD arm than the Kd arm. These results support previous evidence of KdD’s efficacy in relapsed/refractory MM. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
